Literature DB >> 28789355

Prognostic value of Rho GDP dissociation inhibitors in patients with hepatocellular carcinoma following liver transplantation.

Ming-Chun Lai1, Qian-Qian Zhu2, Kwabena-Gyabaah Owusu-Ansah1, Yang-Bo Zhu1, Zhe Yang1, Hai-Yang Xie1, Lin Zhou1, Li-Ming Wu1, Shu-Sen Zheng1.   

Abstract

Rho GDP dissociation inhibitors (GDIs) are pivotal regulators of Rho GTPases, which are essential for tumor progression, yet their role in hepatocellular carcinoma (HCC) remains poorly understood. The purpose of the present study was to assess the role of RhoGDIs in the invasiveness and migration of liver cancer, and to determine their clinical prognostic significances in HCC following liver transplantation (LT). In the present study, the expression of RhoGDIs was assessed using reverse transcription-quantitative polymerase chain reaction and confirmed by western-blot analysis and immunohistochemistry. Their prognostic values were also analyzed, and determined in patients treated with LT. In addition, the functions of RhoGDIs in liver cancer cell line were studied in vitro. As a result, the downregulation of RhoGDI1 and RhoGDI2 at mRNA and protein levels were detected in HCC when compared with that of adjacent noncancerous tissues (P<0.05). However, the level of RhoGDI3 was identified to be similar in tumor and para-carcinoma tissues. Additionally, Kaplan-Meier curves demonstrated that patients with lower expression of RhoGDI1 or RhoGDI2 exhibited significantly increased risk of tumor recurrence following LT (P=0.007 and P=0.006, respectively). Cox proportional hazards model analysis revealed that the decreased expression level of RhoGDI2 was an unfavorable independent prognostic factor (hazard ratio, 3.306; P=0.001). In vitro studies involving the silencing of RhoGDI1 or RhoGDI2 demonstrated a significant increase in the migratory and invasive ability of tumor cells upon the silencing of these genes. Results from the present study indicate that RhoGDI dysregulation is a frequent event in human HCC, and that it promotes cancer progression by stimulating cell migration and invasion. RhoGDI2 may be a prognostic biomarker for patients with HCC following LT, and act as a potential therapeutic target.

Entities:  

Keywords:  Rho guanosine diphosphate dissociation inhibitors 1; RhoGDI2; hepatocellular carcinoma; liver transplantation; prognosis

Year:  2017        PMID: 28789355      PMCID: PMC5529870          DOI: 10.3892/ol.2017.6333

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  GDIs: central regulatory molecules in Rho GTPase activation.

Authors:  Céline DerMardirossian; Gary M Bokoch
Journal:  Trends Cell Biol       Date:  2005-07       Impact factor: 20.808

3.  Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia.

Authors:  Y Wu; K McRoberts; S S Berr; H F Frierson; M Conaway; D Theodorescu
Journal:  Oncogene       Date:  2006-07-31       Impact factor: 9.867

4.  Talin-1 correlates with reduced invasion and migration in human hepatocellular carcinoma cells.

Authors:  Kun-Peng Fang; Jian-Lin Zhang; Yan-Hong Ren; Ye-Ben Qian
Journal:  Asian Pac J Cancer Prev       Date:  2014

5.  Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.

Authors:  Melanie B Thomas; Deborah Jaffe; Michael M Choti; Jacques Belghiti; Steven Curley; Yuman Fong; Gregory Gores; Robert Kerlan; Phillipe Merle; Bert O'Neil; Ronnie Poon; Lawrence Schwartz; Joel Tepper; Francis Yao; Daniel Haller; Margaret Mooney; Alan Venook
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

6.  Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy.

Authors:  Pierre Hainaut; Amelie Plymoth
Journal:  Curr Opin Oncol       Date:  2013-01       Impact factor: 3.645

7.  Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  Ming-chun Lai; Zhe Yang; Lin Zhou; Qian-qian Zhu; Hai-yang Xie; Feng Zhang; Li-ming Wu; Lei-ming Chen; Shu-sen Zheng
Journal:  Med Oncol       Date:  2011-06-16       Impact factor: 3.064

8.  LyGDI is a promising biomarker for ovarian cancer.

Authors:  Hongying Zhen; Shaomin Yang; Hounan Wu; Shuling Wang; Jingqiao Lv; Lijun Ma; Xiaowei Zhang
Journal:  Int J Gynecol Cancer       Date:  2010-04       Impact factor: 3.437

9.  Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma.

Authors:  Liya Ma; Gaixiang Xu; Anna Sotnikova; Monika Szczepanowski; Maciej Giefing; Kristina Krause; Matthias Krams; Reiner Siebert; Jie Jin; Wolfram Klapper
Journal:  Br J Haematol       Date:  2007-10       Impact factor: 6.998

10.  Rho GDP dissociation inhibitor alpha expression correlates with the outcome of CMF treatment in invasive ductal breast cancer.

Authors:  Henrike Ronneburg; Paul N Span; Eva Kantelhardt; Angela Dittmer; Dario Schunke; Hans-Jürgen Holzhausen; Fred C G J Sweep; Jürgen Dittmer
Journal:  Int J Oncol       Date:  2010-02       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.